News | March 06, 2023
Par Drugs and Chemicals receives WHO-GMP certificate
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
Jamnagar’s contributions towards wellness will get a global identity with WHO’s Global Centre for Traditional Medicine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)
